COMPANY PROFILE

Lucence

Precision oncology company dedicated to creating state-of-the-art, highly sensitive liquid biopsy tests for early disease detection and personalized treatment selection

Palo Alto, United StatesFounded 2016Biotech & Life Sciences

Valuation $100–250M Last recorded · 2023

Headcount 100–500 Current team size

Total funding $50–100M Disclosed equity funding

Unlock exact values

About Lucence

Lucence is a pioneering company in the field of precision cancer care, specializing in ultrasensitive and non-invasive liquid biopsy tests. These tests are designed to detect and profile cancer using a single blood draw, making early detection more accessible and affordable. Lucence serves a diverse range of clients, including physicians and patients, who require accurate and actionable insights to guide their medical care. Operating in the healthcare and biotechnology market, Lucence leverages its proprietary technologies to capture both sequence and cell information, providing comprehensive cancer profiling. The company's business model revolves around offering these advanced diagnostic tests, generating revenue through the sale of their liquid biopsy solutions. By focusing on early cancer detection, Lucence aims to transform cancer care and improve patient outcomes.

Source: Dealroom company data

At a glance

Status: Operational
Founded: 2016
Headquarters: Palo Alto, United States
Employees: 105
Open positions: 10
Dealroom signal: 56.6/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Oncology, DNA, Genetics and genomics, Spinout, Genome Engineering, Biotech and Pharma, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn X

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

3 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES A✓Equity / VC	Nov 2019	$20M	$80M	SGInnovate · Boon Hwee Koh · Heliconia Capital Management · IHH Healthcare	—
SEED✓Equity / VC	Jan 2019	$9.2M	$37M	Heliconia Capital Management · Boon Hwee Koh · Lim Kaling	—

Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Lucence website traffic

Latest recorded traffic for Lucence is 4.1K monthly website visits, down 14.6% over the last three months. Lucence's team grew 9.4% over the past year.

Latest monthly visits4.1K 3-month web change-14.6% 1-year team growth+9.4%

Monthly website visitsJun 2020–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom

Scientific Affairs & Market Development Associate (Bahasa Indonesia speaking)3520, West Bayshore Road, 94303 Palo Alto, United States · Marketing & Communication · Sep 7, 2026 Growth & Partnerships Lead3520, West Bayshore Road, 94303 Palo Alto, United States · Business Development · Sep 7, 2026 Sales Executive ()Hong Kong, China, Eastern Asia, Asia · Sales · Aug 31, 2026 Sales Executive ()3520, West Bayshore Road, 94303 Palo Alto, United States · Sales · Aug 28, 2026 People Operations Executive / Senior ExecutiveSingapore, Singapore, South-eastern Asia, Asia · Human Resources · Aug 24, 2026 Marketing & Sales Support Executive ()Singapore, Singapore, South-eastern Asia, Asia · Marketing & Communication · Aug 24, 2026 Marketing & Sales Support Executive3520, West Bayshore Road, 94303 Palo Alto, United States · Marketing & Communication · Aug 23, 2026 Marketing & Sales Support Executive ()3520, West Bayshore Road, 94303 Palo Alto, United States · Marketing & Communication · Aug 23, 2026

8 distinct openings shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
ANAntegenesGenetic tests for personalized cancer risk prevention	Tartu, Estonia	Operational	11	$3.4M	$7M
FEFemtogenixDNA-interactive payloads for antibody-drug conjugates	St Albans, United Kingdom	Operational
SGSinglera GenomicsA developer of 'liquid biopsy' analysis reagents and software, focusing on determing methylation haplotypes across many thousands of genomic locations in cell-free DNA	San Diego, United States	Operational
PGPhase GenomicsPhase Genomics' mission is to help scientists make breakthrough discoveries by providing the most complete, accurate, detailed genomes	Seattle, United States	Operational
SBScenic BiotechGenetic modifier therapies for rare inherited diseases	Amsterdam, Netherlands	Operational
XEXenotheraDeveloping improved immunological treatments using their glyco-humanized antibody platform	Nantes, France	Operational
OGOryzon GenomicsDevelops diagnostic and therapeutic tools	Cornellà de Llobregat, Spain	Operational
INInspirnaBiotechnology company developing drugs for the treatment of cancer	New York City, United States	Operational